FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387380470> ?p ?o ?g. }

• W4387380470 abstract "Abstract Disclosure: A.U. Kulkarni: None. D.T. Patel: None. E.B. Ruby: None. Anti-programmed cell death-1 (Anti-PD1) antibodies (e.g., Pembrolizumab) are immune checkpoint inhibitors that are widely in use for the treatment of many advanced malignancies. This has resulted in various side effects known as irAEs (immune-related adverse events). Endocrine irAEs include hypophysitis, adrenal insufficiency (AI), hypothyroidism, and hyperthyroidism. A 40-yo female with a history of recently diagnosed triple-negative breast cancer, status post chemotherapy, and immunotherapy with Pembrolizumab (last treatment a month prior to presentation) came in with fatigue, weight loss, and persistent vomiting for two weeks. Her initial BP was noted to be 80/50 mmHg, with HR 108bpm. She appeared weak and tired with no other abnormalities on physical exam. The thyroid was normal with no enlargement. Significant labs were creatinine 1.4mg/dL (0.4-1.3mg/dL), corrected calcium 12.8mg/dL, TSH of &lt;0.01mUI/L and fT4 of 4.47ng/dL (0.61-1.12ng/dL) (thyroid tests were previously normal). The patient was admitted to the ICU for hypovolemic shock refractory to IV fluids and endocrinology was consulted for multiple hormonal abnormalities. AKI and hypercalcemia were likely from dehydration as they subsequently resolved with IV fluids. AM cortisol level was low at 0.7ug/dL(3-16ug/dL). The cosyntropin test was positive, confirming AI. ACTH level was &lt;5pg/mL (normal&lt;46pg/mL) indicating a diagnosis of secondary AI, likely from immunotherapy. She was initiated on IV hydrocortisone. MRI brain was obtained to evaluate for hypophysitis which was unremarkable. Further thyroid testing was pursued which showed negative Thyroid peroxidase and anti-thyroglobulin antibodies. Thyroid scan showed a focal hot nodule in the left lobe suspicious for an autonomous nodule. She was started on beta blockers and methimazole with the goal of optimizing her thyroid function prior to her elective mastectomy. Pembrolizumab was discontinued with the plan to re-challenge after surgery. BP stabilized and she was discharged home on hydrocortisone with close outpatient follow-up with Endocrinology and Oncology. The clinical manifestations of Anti-PD1-associated AI are very non-specific and difficult to diagnose as they can be confused with the cancer-related illness itself or chemotherapy. Multiple endocrine abnormalities on initial labs with recent Pembrolizumab therapy in our patient raised suspicion for irAEs. Even though the occurrence of AI from anti-PD1 drugs is extremely rare, being &lt;1%, it can be life-threatening. Very few cases of Anti-PD1-induced thyroid dysfunction have been reported, however further testing in our patient confirmed hyperthyroidism from a toxic thyroid nodule. With the increasing popularity of these drugs, endocrinological complications are on the rise, and we as clinicians need to be vigilant and intervene at an early stage to prevent irreversible and fatal outcomes. Presentation: Friday, June 16, 2023" @default.
• W4387380470 created "2023-10-06" @default.
• W4387380470 creator A5034977414 @default.
• W4387380470 creator A5037550420 @default.
• W4387380470 creator A5071628652 @default.
• W4387380470 date "2023-10-01" @default.
• W4387380470 modified "2023-10-16" @default.
• W4387380470 title "FRI253 Concurrent Adrenal Insufficiency And Hyperthyroidism In A Breast Cancer Patient Treated With Pembrolizumab Therapy" @default.
• W4387380470 doi "https://doi.org/10.1210/jendso/bvad114.248" @default.
• W4387380470 hasPublicationYear "2023" @default.
• W4387380470 type Work @default.
• W4387380470 citedByCount "0" @default.
• W4387380470 crossrefType "journal-article" @default.
• W4387380470 hasAuthorship W4387380470A5034977414 @default.
• W4387380470 hasAuthorship W4387380470A5037550420 @default.
• W4387380470 hasAuthorship W4387380470A5071628652 @default.
• W4387380470 hasBestOaLocation W43873804701 @default.
• W4387380470 hasConcept C121608353 @default.
• W4387380470 hasConcept C126322002 @default.
• W4387380470 hasConcept C134018914 @default.
• W4387380470 hasConcept C197934379 @default.
• W4387380470 hasConcept C2777701055 @default.
• W4387380470 hasConcept C2778129406 @default.
• W4387380470 hasConcept C2780030458 @default.
• W4387380470 hasConcept C2780057760 @default.
• W4387380470 hasConcept C530470458 @default.
• W4387380470 hasConcept C71924100 @default.
• W4387380470 hasConcept C90924648 @default.
• W4387380470 hasConceptScore W4387380470C121608353 @default.
• W4387380470 hasConceptScore W4387380470C126322002 @default.
• W4387380470 hasConceptScore W4387380470C134018914 @default.
• W4387380470 hasConceptScore W4387380470C197934379 @default.
• W4387380470 hasConceptScore W4387380470C2777701055 @default.
• W4387380470 hasConceptScore W4387380470C2778129406 @default.
• W4387380470 hasConceptScore W4387380470C2780030458 @default.
• W4387380470 hasConceptScore W4387380470C2780057760 @default.
• W4387380470 hasConceptScore W4387380470C530470458 @default.
• W4387380470 hasConceptScore W4387380470C71924100 @default.
• W4387380470 hasConceptScore W4387380470C90924648 @default.
• W4387380470 hasIssue "Supplement_1" @default.
• W4387380470 hasLocation W43873804701 @default.
• W4387380470 hasOpenAccess W4387380470 @default.
• W4387380470 hasPrimaryLocation W43873804701 @default.
• W4387380470 hasRelatedWork W2272044596 @default.
• W4387380470 hasRelatedWork W2532961791 @default.
• W4387380470 hasRelatedWork W2799716227 @default.
• W4387380470 hasRelatedWork W2900971926 @default.
• W4387380470 hasRelatedWork W3032782140 @default.
• W4387380470 hasRelatedWork W3094946786 @default.
• W4387380470 hasRelatedWork W4200529536 @default.
• W4387380470 hasRelatedWork W4307261665 @default.
• W4387380470 hasRelatedWork W4362592556 @default.
• W4387380470 hasRelatedWork W4385330227 @default.
• W4387380470 hasVolume "7" @default.
• W4387380470 isParatext "false" @default.
• W4387380470 isRetracted "false" @default.
• W4387380470 workType "article" @default.